Latest Insider Transactions at Dexcom Inc (DXCM)
This section provides a real-time view of insider transactions for Dexcom Inc (DXCM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of DEXCOM INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of DEXCOM INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2022
|
Matthew Vincent Dolan EVP, Strategy & Corporate Dev |
SELL
Open market or private sale
|
Direct |
1,016
-11.52%
|
$418,592
$412.41 P/Share
|
|
Mar 10
2022
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
2,366
-17.12%
|
$948,766
$401.27 P/Share
|
|
Mar 10
2022
|
Chad Patterson EVP Global Marketing |
SELL
Open market or private sale
|
Direct |
776
-4.85%
|
$311,176
$401.27 P/Share
|
|
Mar 09
2022
|
Donald Abbey EVP Global Business Services I |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,429
-2.18%
|
$1,392,174
$406.06 P/Share
|
|
Mar 09
2022
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,430
-6.39%
|
$1,392,580
$406.06 P/Share
|
|
Mar 09
2022
|
Matthew Vincent Dolan EVP, Strategy & Corporate Dev |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,615
-4.11%
|
$655,690
$406.06 P/Share
|
|
Mar 09
2022
|
Paul R Flynn EVP Global Revenue |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,967
-5.45%
|
$1,204,602
$406.06 P/Share
|
|
Mar 09
2022
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,273
-1.83%
|
$1,734,838
$406.06 P/Share
|
|
Mar 09
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,429
-2.99%
|
$1,392,174
$406.06 P/Share
|
|
Mar 09
2022
|
Chad Patterson EVP Global Marketing |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,821
-2.64%
|
$739,326
$406.06 P/Share
|
|
Mar 09
2022
|
Barry J. Regan EVP Operations |
SELL
Sale (or disposition) back to the issuer
|
Direct |
661
-3.65%
|
$268,366
$406.06 P/Share
|
|
Mar 09
2022
|
Kevin R Sayer Chairman, CEO & President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,985
-3.09%
|
$4,053,910
$406.06 P/Share
|
|
Mar 09
2022
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,865
-4.13%
|
$757,190
$406.06 P/Share
|
|
Mar 09
2022
|
Sumi Shrishrimal SVP Chief Risk Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,357
-2.32%
|
$550,942
$406.06 P/Share
|
|
Mar 09
2022
|
Sadie Stern EVP, Chief HR Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
701
-3.74%
|
$284,606
$406.06 P/Share
|
|
Mar 09
2022
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,951
-2.53%
|
$792,106
$406.06 P/Share
|
|
Mar 08
2022
|
Donald Abbey EVP Global Business Services I |
BUY
Grant, award, or other acquisition
|
Direct |
4,984
+8.5%
|
-
|
|
Mar 08
2022
|
Andrew K Balo EVP Regulatory Strategy Clinic |
BUY
Grant, award, or other acquisition
|
Direct |
4,984
+20.74%
|
-
|
|
Mar 08
2022
|
Michael Jon Brown EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,038
+50.0%
|
-
|
|
Mar 08
2022
|
Matthew Vincent Dolan EVP, Strategy & Corporate Dev |
BUY
Grant, award, or other acquisition
|
Direct |
2,889
+21.68%
|
-
|
|
Mar 08
2022
|
Paul R Flynn EVP Global Revenue |
BUY
Grant, award, or other acquisition
|
Direct |
5,297
+21.67%
|
-
|
|
Mar 08
2022
|
Jacob Steven Leach EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,741
+7.86%
|
-
|
|
Mar 08
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
BUY
Grant, award, or other acquisition
|
Direct |
4,984
+11.24%
|
-
|
|
Mar 08
2022
|
Chad Patterson EVP Global Marketing |
BUY
Grant, award, or other acquisition
|
Direct |
5,297
+22.91%
|
-
|
|
Mar 08
2022
|
Barry J. Regan EVP Operations |
BUY
Grant, award, or other acquisition
|
Direct |
4,984
+21.58%
|
-
|
|
Mar 08
2022
|
Kevin R Sayer Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
16,251
+12.78%
|
-
|
|
Mar 08
2022
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,889
+15.55%
|
-
|
|
Mar 08
2022
|
Sumi Shrishrimal SVP Chief Risk Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,889
+16.02%
|
-
|
|
Mar 08
2022
|
Sadie Stern EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,297
+22.02%
|
-
|
|
Mar 08
2022
|
Jereme M Sylvain EVP, Chief Financal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,297
+20.97%
|
-
|
|
Mar 04
2022
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
600
-3.93%
|
$253,200
$422.94 P/Share
|
|
Mar 01
2022
|
Chad Patterson EVP Global Marketing |
SELL
Open market or private sale
|
Direct |
46
-0.37%
|
$18,998
$413.97 P/Share
|
|
Feb 23
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
250
-0.72%
|
$98,500
$394.33 P/Share
|
|
Feb 14
2022
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
3,000
-3.07%
|
$1,254,000
$418.04 P/Share
|
|
Feb 10
2022
|
Barbara Kahn Director |
SELL
Open market or private sale
|
Indirect |
4,666
-5.96%
|
$2,062,372
$442.28 P/Share
|
|
Jan 24
2022
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
250
-0.72%
|
$104,000
$416.77 P/Share
|
|
Jan 18
2022
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
22,674
-10.22%
|
$9,885,864
$436.93 P/Share
|
|
Jan 18
2022
|
Kevin R Sayer Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
38,586
+24.75%
|
-
|
|
Dec 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
250
-0.71%
|
$143,250
$573.91 P/Share
|
|
Dec 15
2021
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
3,000
-0.26%
|
$1,608,000
$536.15 P/Share
|
|
Dec 15
2021
|
Barry J. Regan EVP Operations |
BUY
Grant, award, or other acquisition
|
Direct |
1,671
+11.29%
|
-
|
|
Dec 15
2021
|
Sadie Stern EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,671
+11.04%
|
-
|
|
Dec 15
2021
|
Chad Patterson EVP Global Marketing |
BUY
Grant, award, or other acquisition
|
Direct |
2,925
+18.93%
|
-
|
|
Dec 15
2021
|
Paul R Flynn EVP Global Revenue |
BUY
Grant, award, or other acquisition
|
Direct |
2,925
+17.43%
|
-
|
|
Dec 15
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,925
+16.12%
|
-
|
|
Dec 15
2021
|
Jacob Steven Leach EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,925
+3.89%
|
-
|
|
Dec 14
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Bona fide gift
|
Direct |
5,459
-13.45%
|
-
|
|
Dec 13
2021
|
Barry J. Regan EVP Operations |
SELL
Open market or private sale
|
Direct |
1,214
-9.58%
|
$683,482
$563.93 P/Share
|
|
Dec 06
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
600
-4.65%
|
$310,200
$517.59 P/Share
|
|
Dec 01
2021
|
Mark G Foletta Director |
SELL
Open market or private sale
|
Indirect |
500
-0.49%
|
$281,500
$563.37 P/Share
|